Search PubMed⌕ Search

Biomedical subjects

S Shadomy

Publications and source records attributed to S Shadomy.

At least 73 records · Page 4Linked to original sources
PubMed1977

In vitro activities of five oral cephalosporins against aerobic pathogenic bacteria.

Cefaclor (Lilly 99638) and cefatrizine (BL-S640, SK&F 70771) are orally absorbed, broad-spectrum semisynthetic cephalosporins. They were compared in vitro with cephalexin, cephaloglycin, and cepharadine against a variety of aerobic pathogenic bacteria by an agar dilution procedure. Cefaclor and cefatrizine were found to be similar or superior to cephalexin, cephaloglycin, and cephradine in terms of activity against gram-positive cocci other than enterococci. Only cefatrizine demonstrated any potentially useful activity against some susceptible isolates of enterococci. Cefaclor and cefatrizine also were highly active, equally or more so than the other oral cephalosporins, against several gram-negative species including Escherichia coli, Enterobacter aerogenes, and Klebsiella pneumoniae. None of the cephalosporins were particularly active against Enterobacter cloacae. Both cefaclor and cefatrizine were active against Proteus mirabilis; cefatrizine was uniquely active against indolepositive Proteus species.

Aerobiosis↗
PubMed1977

Laboratory evaluation of serological tests for systemic candidiasis: a cooperative study.

Three serological tests for candidiasis, agar gel diffusion (AGD-1), whole cell agglutination (AGGL-1), and latex agglutination (LAT), were evaluated by six laboratories with 100 coded sera. In addition, each of six laboratories performed a test of its choice, either the AGD-2, the AGD-3, the AGGL-2, or one of three counterimmunoelectrophoresis (CEP) methods (CEP-1, CEP-2, and CEP-3). Results are presented by laboratory for a group of 53 "candida-involved" cases (33 proven, 14 presumptive, and 6 probable) and 47 negative controls (41 normal and 6 other disease states). The AGD-1 test produced an overall average of 85.1% positive results in the candida-involved group and 5.0% positives in the control group. The LAT produced an overall average of 89.0% positives in the candida-involved group and 17.4% positives in the controls. The AGGL-1 test produced an overall average of 63.8% positives in the candida-involved group, with 12.3% positives in the controls. In the individual tests, the best performance was shown by the CEP-3 test (92.5% positives in the candida-involved group and 2.1% positives in controls) and the CEP-1 test (88.7% positive in the candida-involved group and no positives in the controls). The tests with the highest sensitivity were the AGGL-2 and CEP-2 (94.3 and 96.2%, respectively). These tests were also the least specific (80.9 and 76.6%, respectively). In the three common tests, the AGD-1 was the most reproducible, whereas the AGGL-1 produced considerable laboratory-to-laboratory variation. Since cell-free extracts of mechanically disrupted C. albicans were used for the LAT and all the AGD and CEP tests, the difference in performance was considered to be mainly due to antigenic composition and the conditions of the test. The results of this study confirm the value of serological tests for the diagnosis of systemic candidiasis, but point out the need for standardized reagents.

Agglutination Tests↗
PubMed1977

Availability of active amphotericin B after filtration through membrane filters.

The availability of active amphotericin B after filtration of the intravenous form of the drug through in-line filters was examined. Filtration through circular filters of 25-mm diameter and 0.45-micronm pore size resulted in little loss of active drug, although a marked decrease in flow occurred with time. Filtration through either circular or cylindrical filters with 0.22-micronm pores resulted both in significant losses of active drug and in marked decreases in flow. Thus, membrane filters of 0.22-micronm pore size are not suitable for use in intravenous administration of amphotericin B. The use of filters of 0.45-micronm pore size is appropriate only in situations in which decreased flow is acceptable.

Amphotericin B↗
PubMed1976

Josamycin and rosamicin: in vitro comparisons with erythromycin and clindamycin.

The macrolide antibiotics josamycin and rosamicin were compared in vitro with erythromycin for activity against Staphylococcus aureus, S. epidermidis, and enterococci and with clindamycin for activity against a variety of anaerobic organisms. Rosamicin and erythromycin were similar in activity and superior to josamycin against aerobic cocci. Most isolates of S. aureus (96%), S. epidermidis (79%), and the enterococci (87%) were inhibited by 1.56 mug of either of the new macrolide compounds per ml. Clindamycin was the most active compound against the anaerobic organisms.

Aminoglycosides↗
PubMed1976

In vitro studies with sisomicin and gentamicin.

Sisomicin and gentamicin were tested in vitro against 222 clinical isolates of pathogenic bacteria using the ICS agar dilution procedure. The two drugs were comparable in terms of overall activity although statistical analyses of the data revealed significant differences in their activity against several genera. Sisomicin was significantly more active against Pseudomonas aeruginosa (p less than 0.001), Proteus mirabilis (p less than 0.005), and Escherichia coli (p less than 0.01); gentamicin was significantly more active against Klebsiella (p less than 0.001). In most instances, 4.0 mug/ml of either drug was inhibitory for 90% or more of the isolates of each genus tested.

Anti-Bacterial Agents↗
PubMed1976

Brain abscess caused by Cladosporium trichoides.

In 17 previously reported cases of cladosporiosis, no reliable therapy was described, and death occurred usually within one year of diagnosis. Pretreatment isolates from our two patients were inhibited by 6.2 mug/ml and 3.1mug/ml of flucytosine, respectively. Although both patients died, postmortem examination results showed that in one patient, the fungus had been eradicated. In the other patient, C trichoides that was isolated at postmortem examination was resistant to flucytosine treatment.

Adolescent↗
PubMed1975

Therapy of cryptococcosis with a combination of flucytosine and amphotericin B.

In a prospective study from May 1971 to November 1973, 20 consecutive patients with a diagnosis of disseminated cryptococcosis were treated for six weeks with a combination of amphotericin B (20 mg daily) intravenously and flucytosine (150 mg/kg daily) orally. Fifteen patients has culturally docummented Cryptococcus neoformans meningitis, and three died of infection early in therapy. Of the remaining 12 patients, eight were alive and well eight to 34 months after therapy, and four died of other causes. None of the surviving patients has relapsed. Hematologic complications developed in nine patients, three of whom had no underlying lymphoreticular disorder or therapy with known cytotoxic agents. Renal insufficiency of mild degree occurred in only six patients. A shorter period of hospitalization and reduction in toxicity of amphotericin B suggest that combined therapy is a safe and efficacious alternative to other regimens.

Adult↗
PubMed1975

New method for susceptibility testing with antifungal agents.

A new method for the determination of minimal inhibitory and fungicidal concentrations of antifungal agents for filamentous fungi is described. 5-Fluorocytosine (5-FC) was used as a representative agent and was tested against the following genera: Allescheria, Aspergillus, Cladosporium, Fonsecaea, and Phialophora. 5-FC was found to be inhibitory but not fungicidal for many of the fungi tested, including eight of clinical origin.

Antifungal Agents↗
PubMed1975

In vitro studies with combinations of 5-fluorocytosine and amphotericin B.

Synergistic antifungal activity of 5-fluorocytosine (5-FC) and amphotericin B was studied using an abbreviated checkerboard titration scheme. 5-FC was titrated in twofold increments (100 to 0.05 mug/ml) in the absence and presence of graded increments of amphotericin B (1.0. 0.5, 0.1, 0.05, and 0.01 mug/ml) in buffered yeast nitrogen base. A limited number of experiments were performed using expanded dual titration checkerboard schemes and growth curve studies. Forty-eight isolates of yeastlike organisms were tested; two were inhibited by the buffer system. Evidence of synergy, as indicated by a fourfold or greater reduction of the minimal inhibitory concentration of 5-FC in the presence of subinhibitory concentrations of amphotericin B, was seen with 11 of 46 isolates, or 24%, at the fungistatic level and with three isolates, or 7% at the fungicidal level. Indifferent results were obtained for 44 and 74% of the isolates, respectively, at the fungistatic and fungicidal levels. Antagonism was observed with three isolates.

Amphotericin B↗
PubMed1975

Stability of amphotericin B in polyvinvl chloride intravenous infusion bags.

The stability of solutions of amphotericin B as prepared for intravenous use in glass and polyvinyl chloride plastic (PVC) containers was studied. Four conditions were tested: contained within glass and exposed to light; contained in glass and shielded from light; contained in PVC and exposed to light; contained in PVC and shielded from light. Bioassays were performed on specimens collected from the containers periodically during 24 hours. Results of the bioassays revealed no significant loss of activity under any of the test conditions.

Amphotericin B↗
PubMed1974

Fungal infections.

Explore the source record for details and available documents.

Antifungal Agents↗
PubMed1974

In vitro studies with cefazolin.

Susceptibilities of 259 isolates of pathogenic bacteria to cefazolin were measured by broth and agar dilution procedures. Beta-hemolytic streptococci were inhibited by 0.25 mug/ml, whereas Staphylococcus aureus and alphahemolytic streptococci were inhibited by 2.0 mug/ml. Enterococci were resistant to less than 32 mug/ml. Wide variation was seen with gram-negative species. Most isolates of Klebsiella species and Proteus mirabilis were inhibited by 4.0 or 8.0 mug/ml. Escherichia coli were less susceptible, and most isolates of Pseudomonas aeruginosa, Serratia species, and Enterobacter species were resistant to 128 mug/ml.

Bacteria↗
PubMed1973

In vitro activity of 5-fluorocytosine against Candida and Torulopsis species.

One hundred yeasts were studied. Tests included detailed identification and determination of 24- and 48-hr minimal inhibitory concentrations and minimal fungicidal concentrations of 5-fluorocytosine (5-FC). Final identifications included 57 isolates of Candida albicans, 15 isolates of C. tropicalis, 13 isolates of C. parapsilosis, 7 isolates of Torulopsis glabrata, 3 isolates of C. guilliermondii, 2 isolates each of C. stellatoidea and Cryptococcus neoformans, and 1 isolate of Candida krusei. Twenty-three original identifications were in error; these involved mostly C. albicans, C. tropicalis, C. parapsilosis, and T. glabrata. Inhibitory end point readings based on 24 hr of incubation were misleading. Whereas 79 of 91 isolates of Candida appeared to be inhibited at 24 hr by 12.5 mug or less of 5-FC/ml, only 52 were inhibited at 48 hr; whereas only 12 isolates appeared to be resistant to 100 mug/ml after 24 hr, 37 were resistant after 48 hr. Susceptibility varied amount the different species. C. tropicalis was the most susceptible, with 10 of 15 isolates (66.7%) being inhibited by 12.5 mug or less/ml and 7 (46.7%) being killed by 100 mug or less/ml. C. albicans was similarily susceptible; 33 of 57 isolates (57.9%) were inhibited by 12.5 mug or less/ml and 25 (43.9%) were killed by 100 mug or less/ml. C. parapsilosis was quite resistant, as only 4 of 13 isolates (30.8%) were inhibited by 12.5 mug or less/ml and 3 (23.1%) were killed by 100 mug or less/ml.

Antifungal Agents↗